What insurance policy changes affect HCPCS J7171?

There are 14 tracked policy changes affecting HCPCS J7171, including updates from UnitedHealthcare, Humana, Anthem BCBS. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS J7171?

Payers that have issued tracked updates for HCPCS J7171 include: UnitedHealthcare, Humana, Anthem BCBS, Aetna, Harvard Pilgrim Health Care, Independence Blue Cross.

How do I get notified when HCPCS J7171 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS J7171. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for HCPCS J7171?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

J7171 — Injection, adamts13, recombinant-krhn, 10 iu: Insurance Policy Changes

J7171 Insurance Policy Changes

HCPCS J7171 is officially defined as "Injection, adamts13, recombinant-krhn, 10 iu." HCPCS J7171 is referenced in 14 tracked payer policy changes from UnitedHealthcare, Humana, and 4 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J7171 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact

[Ohio] May 2026 Provider Newsletter

Anthem BCBS·Effective Jun 1, 2026

This is a comprehensive Ohio provider newsletter (May 2026) containing multiple policy updates across prior authorization requirements, billing code usage, clinical guidelines, and administrative procedures. Key changes include: modifier requirements for E&M services (effective July 1, 2026 for Medicare Advantage; August 1, 2026 for Commercial/Medicaid), JW/JZ modifier corrections for drug waste billing (June 1, 2026), prior authorization updates for multiple service lines through Carelon, and clinical policy updates effective May-October 2026. Several items note 'Material Amendments to Contract and/or Change to Prior Authorization Requirements' requiring immediate attention.

J7171 Insurance Policy Changes

Evenity ® (Romosozumab-Aqqg)

Evenity ® (Romosozumab-Aqqg)

Ultomiris® (ravulizumab-cwvz) (New)

[Ohio] May 2026 Provider Newsletter

IVIG (immune globulin) (Revised)

Immune Globulins for Post-Exposure Prophylaxis (CPB 0544, reviewed 2025-12-23)

Lemtrada® (alemtuzumab) (Revised)

Elaprase® (idursulfase) (Revised)

Factor VIII Replacement Products (Hemophilia A) (Revised)

ADAMTS13, Recombinant-krhn (Adzynma) (CPB 1050, reviewed 2025-12-03)

Lemtrada® (alemtuzumab) (New)

Pharmacy coverage changes

MA08.171, ADAMTS13, recombinant-krhn (Adzynma)

08.02.21, ADAMTS13, recombinant-krhn (Adzynma)